Valneva Says UK Revokes Chikungunya Virus Vaccine's Marketing Authorization; Shares Down Pre-Bell
MT newswire2026/10/08 09:2305:23 AM EDT, 10/08/2026 (MT Newswires) -- Valneva (VALN) shares were 4.6% lower in premarket activity Thursday after the company said overnight the UK revoked the marketing authorization for chikungunya virus vaccine Ixchiq. The decision followed a further benefit-risk assessment by the UK's Commission on Human Medicines based on previous safety data, Valneva said Wednesday. The company has not actively distributed the vaccine in the UK for several months due to low traveler demand and expects no product recall costs and only "minimal impact" on revenue, it said. Valneva will not appeal the decision, citing its limited financial and commercial impact.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
